HepatitisBvirus(HBV)isasignificantglobalpathogenandefficientcureforHBVpatientsisstillachallenginggoal.Wepreviouslyreportedthatacidicmucopolysaccharidefromstichopusjaponicusselenka(SJAMP)couldinhibitHBsAgandHBeAgexpressioninvitro.However,thepotentialanti-HBVeffectsofSJAMPinvivohavenotyetbeenexplored.Inthisstudy,weshowthatSJAMPexhibitspotentanti-HBVactivityinHBVtransgenicmiceinadose-dependentmanner.Specifically,sixtyHBVtransgenicmaleBALB/cmicewererandomlyselectedtoreceivethetreatmentofPBS,lowdoseSJAMP(30mgkg-1),middledoseSJAMP(40mgkg-1),highdoseSJAMP(50mgkg-1)andIFN(45IUkg-1)for30d.SJAMPtreatmentsuppressedserumHBV-DNA,andliverHBsAgandHBcAglevelsinHBV-transgenicmice.ThepresentstudyhighlightsthepotentialapplicationofSJAMPinHBVtherapy.